Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1675 of 2529 entries
View as:

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Phase: N/A Priority: Normal
NCT ID: NCT01470989 Org: User:
Start: 11/30/11 End: 05/31/13 Due: 05/31/14

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Phase: N/A Priority: Normal
NCT ID: NCT04817618 Org: User:
Start: 07/28/21 End: 07/04/26 Due: 07/04/27

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Phase: N/A Priority: Normal
NCT ID: NCT04597632 Org: User:
Start: 12/16/20 End: 03/28/23 Due: 03/28/24

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT00975715 Org: User:
Start: 09/30/09 End: 10/31/12 Due: 10/31/13

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00417170 Org: User:
Start: 10/31/07 End: 07/31/10 Due: 07/31/11

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00879658 Org: User:
Start: 03/30/09 End: 05/04/11 Due: 05/04/12

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT01335035 Org: User:
Start: 12/31/08 End: - Due: -

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01375179 Org: User:
Start: 12/31/10 End: 05/31/12 Due: 05/31/13

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Phase: N/A Priority: Normal
NCT ID: NCT05199090 Org: User:
Start: 02/10/22 End: 05/11/23 Due: 05/11/24

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00117507 Org: User:
Start: 09/30/05 End: 01/31/08 Due: 01/31/09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03207867 Org: User:
Start: 08/28/17 End: 02/14/23 Due: 02/14/24

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Phase: N/A Priority: Normal
NCT ID: NCT05621733 Org: User:
Start: 04/07/23 End: 05/13/26 Due: 05/13/27

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Phase: N/A Priority: Normal
NCT ID: NCT06031844 Org: User:
Start: 10/16/23 End: 12/23/24 Due: 12/23/25

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)

Phase: N/A Priority: Normal
NCT ID: NCT01483014 Org: User:
Start: 06/30/08 End: 01/31/12 Due: 01/31/13

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Phase: N/A Priority: Normal
NCT ID: NCT06392763 Org: User:
Start: 08/03/21 End: 04/28/23 Due: 04/28/24

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Phase: N/A Priority: Normal
NCT ID: NCT01351103 Org: User:
Start: 12/01/11 End: 06/17/24 Due: 06/17/25

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04557462 Org: User:
Start: 09/20/21 End: 11/11/32 Due: 11/11/33

A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT06625333 Org: User:
Start: 10/11/24 End: 10/30/27 Due: 10/30/28

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT00792805 Org: User:
Start: 11/30/08 End: 02/28/10 Due: 02/28/11

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Phase: N/A Priority: Normal
NCT ID: NCT02584933 Org: User:
Start: 12/11/15 End: 06/09/27 Due: 06/09/28

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT04480853 Org: User:
Start: 10/12/20 End: 01/27/26 Due: 01/27/27

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Phase: N/A Priority: Normal
NCT ID: NCT03249714 Org: User:
Start: 03/15/18 End: 07/29/20 Due: 07/29/21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05870579 Org: User:
Start: 11/13/23 End: 01/26/32 Due: 01/26/33

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT01035229 Org: User:
Start: 04/30/10 End: 10/31/13 Due: 10/31/14

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Phase: N/A Priority: Normal
NCT ID: NCT01775124 Org: User:
Start: 02/22/13 End: 11/23/15 Due: 11/23/16